ESMO E-Learning: Overview of the Diagnosis and Treatment of GI NETs

Learning Objectives

  • Provide an update on classification, clinical presentation, diagnosis and assessment in patients with gastrointestinal neuroendocrine tumours (NETs)
  • Describe the importance of specific biologic features in the development of new treatments for patients with gastrointestinal NETs
  • Explain data from recent clinical trials in patients with gastrointestinal NETs

 

Title Duration Content CME Points CME Test
Overview of the diagnosis and treatment of GI NETs 60 min. 73 slides 1 Take Test
toumpanakis-christos
Christos Toumpanakis
Read more

In this E-Learning module, the author provides a comprehensive overview of the classification, clinical presentation, diagnosis, assessment and treatment of gastrointestinal neuroendocrine tumours (NETs). The treatment options are in particular supported by reviewing evidence from the clinical studies for a range of medical, loco-regional and nuclear medicine and radiation options. 

NETs are rare, usually slow growing, may secrete hormones, may have somatostatin receptors and can be treated with more than one option. In this module, the author provides a basis of histopathological and clinical classification of NETs and reviews the features of gastrointestinal NETs in terms of various localisations. Furthermore, the author reviews specific and non-specific symptoms in the clinical manifestation and details the biochemical tests. The potential role of novel biomarkers is emphasized as well. 

Besides conventional imaging (anatomic and endoscopic) a significant part of the module is dedicated to the molecular imaging. The author first gives details about somatostatin receptors in NETs. In particular, octreoscan reveals the primary in 50-80%and the metastases in 95%of patients. It can predict the response with somatostatin analogues. However, it shows low sensitivity in poorly-differentiated NETs, small duodenal gastrinomas and insulinomas. 18F- FDG – PET is useful for evaluating the extension of the disease. Furthermore, the author provides specificities of PET scans specific for NETs, namely PET with 68Ga-somatostatin analogues, 18F-DOPA PET, 11C 5-HTP PET and combination of PETs for the evaluation of NET heterogeneity. The next chapter is dedicated to novel molecular imaging (imaging with somatostatin receptor antagonists). In particular, one of the strengths of this module is the provision of a very detailed diagnostic algorithm. 

The treatment of NETs provides medical control of the patient’s symptoms. The goal is a resection of the tumour primary and if possible, metastatic lesions. The goal of treatment in advanced setting is the control of tumour growth, as well as the improvement and maintenance of patient’s quality of life. 

The author provides a state-of-the-art in terms of medical therapy options (somatostatin analogues, interferon-α, molecular targeted therapies and systemic chemotherapy), loco-regional therapy options (radiofrequency ablation, embolization/chemoembolization/radioembolization), and nuclear medicine and radiation therapy (tumour-targeted radioactive therapy, external radiation). 

A particular emphasis in the module is devoted to a multidisciplinary team approach to NETs, in terms of an accurate diagnosis and staging, evaluation of performance status and quality of life, consensus agreement on treatment plan, continuous reassessment, discussion and peer review of the individualised treatment plan.

Last update: 30 August 2018

The author has reported honoraria for lectures and Educational grants for the Royal Free Hospital NET Unit from Ipsen, Novartis and AAA-Pharma Inc. He serves on the Advisory Board of Lexicon Pharmaceuticals Inc.